Key Highlights
- 4SC AG is pioneering in the development of HDAC inhibitors for cancer treatment, with a focus on cutaneous T-cell lymphoma (CTCL).
- The company's lead product, Resminostat, has shown potential in inhibiting tumor growth and strengthening the immune response to cancer.
- The RESMAIN study is a pivotal clinical trial that could significantly impact the treatment landscape for advanced-stage CTCL.
- 4SC AG's innovative approach to cancer treatment positions it as a leader in the field of oncology therapeutics.
- The company's collaboration with Yakult Honsha in Japan highlights its global reach and commitment to advancing cancer treatment options.
About 4SC AG
4SC AG is a biotechnology company headquartered in Planegg-Martinsried near Munich, Germany. The company specializes in developing innovative cancer treatments, with a focus on histone deacetylase (HDAC) inhibitors. Their lead product, Resminostat, is being investigated for its potential in treating cutaneous T-cell lymphoma (CTCL). The pivotal RESMAIN study, conducted across Europe and Japan, aims to evaluate Resminostat's efficacy in maintaining disease control in advanced-stage CTCL patients. With a team of 30 FTEs, 4SC AG is listed on the Prime Standard of the Frankfurt Stock Exchange.
CTCL is a rare form of lymphoma that primarily affects the skin and can progress to involve lymph nodes, blood, and visceral organs. The disease is currently not curable, and treatment options for advanced-stage CTCL are limited. 4SC AG's Resminostat aims to address this unmet medical need by potentially offering a new approach to treating CTCL and improving patient outcomes.
The RESMAIN study is a significant clinical trial involving over 190 patients across more than 50 clinical centers in 11 European countries and Japan. The study's goal is to assess Resminostat's effectiveness in maintaining disease control and improving the quality of life for patients with advanced-stage CTCL.
Why Contact 4SC AG?
B2B professionals should contact 4SC AG for opportunities in oncology therapeutics, particularly in the development of innovative cancer treatments. The company's focus on HDAC inhibitors and its ongoing clinical trials present potential partnerships and vendor opportunities in the biotechnology sector.
Who Should Contact 4SC AG for Business?
Sales teams selling oncology therapeutics, pharmaceutical companies interested in cancer treatment innovations, and recruiters seeking roles in biotechnology and clinical research should reach out to 4SC AG.
Categories
- 4SC AG
- Resminostat
- HDAC inhibitors
- CTCL treatment
- Clinical trials
- Cancer treatment
- Biotechnology
- Oncology
- Resminostat study
- Advanced-stage CTCL
More Biotechnology Companies
Frequently Asked Questions
- How many employees does 4SC AG have?
- 4SC AG has approximately 27 employees.
- Where is 4SC AG headquartered?
- Planegg-martinsried, Germany
- What industry is 4SC AG in?
- 4SC AG operates in Biotechnology, Oncology Therapeutics, Clinical Trials.
- When was 4SC AG founded?
- 4SC AG was founded in 1997.
- What is the email format at 4SC AG?
- 4SC AG uses the email format first.last@4sc.com.
- Is 4SC AG still active?
- Yes, 4SC AG was verified as an active company on February 2, 2026. Data Surfer regularly validates company information to ensure accuracy.
- How do I sell to 4SC AG?
- Research 4SC AG's priorities and goals, identify the right decision makers and champions, monitor for buying signals, and reach out at the right time with verified contact details. Learn how Data Surfer helps.
Ready to Sell to 4SC AG?
Get qualified leads in 10 minutes. Research prospects, find decision makers, and monitor for the perfect moment to reach out.
Last verified: February 2, 2026
Backed by startup programs from
Connect with 4SC AG